17β-Estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin

This publication has 19 references indexed in Scilit:

• Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists?
  Journal of Clinical Endocrinology & Metabolism, 1990
• Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol
  Fertility and Sterility, 1989
• A new way to induce oestrogen-deficiency osteopaenia in the rat: comparison of the effects of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition
  Journal of Endocrinology, 1989
• Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin
  Fertility and Sterility, 1989
• Suppression of Postmenopausal Ovarian Steroidogenesis With the Luteinizing Hormone-Releasing Hormone Agonist Goserelin*
  Journal of Clinical Endocrinology & Metabolism, 1988
• Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis
  New England Journal of Medicine, 1988
• Increased Bone Turnover During Gonadotropin-Releasing Hormone Superagonist-Induced Ovulation Inhibition*
  Journal of Clinical Endocrinology & Metabolism, 1987
• Hypogonadism induced by luteinising hormone releasing hormone agonist analogues: effects on bone density in premenopausal women.
  BMJ, 1987
• LHRH ANALOGUES AND BONE LOSS
  The Lancet, 1987
• Effects of NaCl on Calcium Balance, Parathyroid Function and Hydroxyproline Excretion in Prednisolone-Treated Rats Consuming Low Calcium Diet
  Journal of Nutrition, 1986